SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 26171.
  • 2
    Salvarani C, Cimino L, Macchioni PL, Consonni D, Cantini F, Bajocchi GL, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005; 53: 2937.
  • 3
    Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 28392.
  • 4
    Nesher G, Berkun Y, Mates M, Baras M, Nesher R, Rubinow A, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004; 83: 11422.
  • 5
    Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497504.
  • 6
    Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 2632.
  • 7
    Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 1609.
  • 8
    Ruegg S, Engelter S, Jeanneret C, Hetzel A, Probst A, Steck AJ, et al. Bilateral vertebral artery occlusion resulting from giant cell arteritis: reports of 3 cases and review of the literature. Medicine (Baltimore) 2003; 82: 112.
  • 9
    Nesher G, Berkun Y, Mates M, Baran M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 13327.
  • 10
    Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 33069.
  • 11
    Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 45766.
  • 12
    Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994; 72: 115.
  • 13
    Phillips DR, Charo IF, Parise LV, Fizgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 83143.
  • 14
    Thornton MA, Poncz M, Korostishevsky M, Yakobson E, Usher S, Seligsohn U, et al. The human platelet αIIb gene is not closely linked to its integrin partner β3. Blood 1999; 94: 203947.
  • 15
    Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19: 11427.
  • 16
    Grove EL, Orntoft TF, Lassen JF, Jensen HK, Kristensen SD. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J Intern Med 2004; 255: 63744.
  • 17
    Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG, Copenhagen City Heart Study. Platelet glycoprotein IIb/IIIa PlA2/PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 2003; 42: 6617.
  • 18
    Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottiger C, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 100510.
  • 19
    Slowik A, Dziedzic T, Turaj W, Pera J, Glodzik-Sobanska L, Szermer P, et al. A2 allele of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke 2004; 35: 158993.
  • 20
    Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 20515.
  • 21
    Gonzalez-Gay MA, Boiardi L, Garcia-Porrua C, Macchioni P, Amor-Dorado JC, Salvarani C. Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern Europe. J Rheumatol 2004; 31: 5203.
  • 22
    Tanaka S, Taniue A, Nagao N, Ohnoki S, Shibata H, Okubo Y, et al. Simultaneous DNA typing of human platelet antigens 2, 3 and 4 by an allele-specific PCR method. Vox Sang 1995; 68: 22530.
  • 23
    Salvarani C, Giannini C, Miller DV, Hunder G. Giant cell arteritis: involvement of intracranial arteries. Arthritis Rheum 2006; 55: 9859.
  • 24
    Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004; 83: 3427.
  • 25
    Machado EB, Gabriel SE, Beard CM, Michet CJ, O'Fallon WM, Ballard DJ. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease? Int J Epidemiol 1989; 18: 83641.
  • 26
    Duhaut P, Pinede L, Demolombe-Rague S, Loire R, Seydoux D, Ninet J, et al, on behalf of the Groupe de Recherchesur l'Arterite a Cellules Geantes. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Arthritis Rheum 1998; 41: 19605.
  • 27
    Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Gonzalez-Gay MA. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. J Rheumatol 2006; 33: 748.
  • 28
    Uddhammar AC. Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 2000; 18 Suppl 20: S323.
  • 29
    Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005; 32: 173741.
  • 30
    Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Amoli MM, Llorca J, et al. Interferon-γ gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004; 22 Suppl 36: S1820.
  • 31
    Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 337884.
  • 32
    Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, et al. Vitronectin receptor (αvβ3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 180918.
  • 33
    Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), αvβ3 integrin, and GPIbα. J Exp Med 1998; 187: 32939.
  • 34
    Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 177881.
  • 35
    Von dem Borne AE, Decary F. Nomenclature of platelet-specific antigens [letter]. Transfusion 1990; 30: 477.
  • 36
    Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PlA1/PlA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85: 62633.
  • 37
    Sobel RE, Bray PF, Richardson C, Petri M, Salmon JE. The platelet glycoprotein IIIA polymorphism PlA2 and risk of thrombotic events in patients with antiphospholipid antibodies [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S172.
  • 38
    Tolusso B, Fabris M, Gremese E, Mosca M, Rovere-Querini P, Ferraccioli GF. Platelet GPIIb/IIIa (PlA1/2) polymorphism in SLE: clinical and laboratory association [letter]. Ann Rheum Dis 2003; 62: 7812.
  • 39
    Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa PlA polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 10138.
  • 40
    Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006; 47: 5416.
  • 41
    Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 9657.
  • 42
    Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E. Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother 2005; 39: 10138.